Aandeel ANTH ANTHERA PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Anthera Pharmaceuticals, Inc.

Aandelen

ANTH

US03674U3005

Beurs gesloten - OTC Markets
Andere beurzen
 21:50:58 24-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,000001 USD -.--% Intraday-grafiek van Anthera Pharmaceuticals, Inc. -.--% -98,51%
2018 Transcript : Anthera Pharmaceuticals, Inc. - Special Call
2016 Transcript : Anthera Pharmaceuticals, Inc. - Special Call

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura
Anthera Mulls Acquisitions
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
Anthera Pharmaceuticals, Inc. Announces Executive Changes
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ANTH
  4. Nieuws Anthera Pharmaceuticals, Inc.
  5. Andere talen